美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

ALPS Medical Breakthroughs ETF

67.66

+0.35000.52%

盘后：67.660.00000.00%19:51 EDT

成交量：2.67万

成交额：179.78万

市值：2.44亿

市盈率：- -

高：67.67

开：66.98

低：66.96

收：67.31

52周最高：70.85

52周最低：35.43

股本：360.00万

流通股本：360.00万

量比：0.81

换手率：0.74%

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻公告

109亿美元重磅收购Apogee(APGE.US)落地！艾伯维(ABBV.US)完成2019年以来最大并购，预计2032年起贡献收益

109亿美元重磅收购Apogee(APGE.US)落地！艾伯维(ABBV.US)完成2019年以来最大并购，预计2032年起贡献收益

美股异动丨诺华制药涨超7%，多发性硬化症口服药后期临床试验结果积极

药闻 | 英硅智能上市后首份半年报扭亏创新药研发加速拥抱AI

联环药业上半年扭亏为盈集采续采与创新药研发协同推进

博济医药2026年半年报：创新药研发需求复苏，在手订单充足，经营现金流明显下滑

中国银河证券：实验动物为创新药研发刚需小鼠+猴双主线高景气

百花医药股价严重异常波动：主营小分子化学仿制药CRO业务不涉及创新药研发

百花医药(600721.SH)：不涉及创新药研发

百花医药(600721.SH)：不涉及创新药研发

东方证券：AI重构创新药研发底座国内相关产业链公司亦有望受益

券商观点：艾伯维免疫学研发管线实力雄厚，将支撑营收增长

艾伯维因收购Apogee下调2026年盈利预期，第二季度业绩超出预期

创新药研发加速遇“猴荒”

ANI Pharmaceuticals 宣布拟就CG Oncology相关裁决提出上诉

英硅智能早盘涨超7% 与康哲药业达成AI+创新药研发新合作

（活力中国调研行）上海生物医药产业规模破万亿张江药谷青年人才成创新药研发主力

中国新闻网

翰思艾泰-B(03378)：拟与华科前沿交叉研究中心打造新一代AI驱动的创新药研发范式

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/SBIO/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBIO\",,,,,undefined,":{"symbol":"SBIO","market":"US","secType":"STK","nameCN":"ALPS Medical Breakthroughs ETF","latestPrice":67.66,"timestamp":1788552000000,"preClose":67.31,"halted":0,"volume":26679,"hourTrading":{"tag":"盘后","latestPrice":67.66,"preClose":67.66,"latestTime":"19:51 EDT","volume":124,"amount":8385.21,"timestamp":1788565888060,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.005199821720398073,"floatShares":3600000,"shares":3600000,"eps":0,"marketStatus":"已收盘","change":0.35,"latestTime":"09-04 16:00:00 EDT","open":66.98,"high":67.665,"low":66.96,"amount":1797845.892666,"amplitude":0.010474,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1788854400000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":67.31,"sharesOutstanding":2675000,"nav":67.36,"aum":242478255.23,"bidAskSpread":0.001889,"preHourTrading":{"tag":"盘前","latestPrice":67.57,"preClose":67.31,"latestTime":"07:37 EDT","volume":3,"amount":202.70999999999998,"timestamp":1788521835899,"change":0.26,"changeRate":0.003863,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":67.66,"preClose":67.66,"latestTime":"19:51 EDT","volume":124,"amount":8385.21,"timestamp":1788565888060,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.807192,"impliedVol":0.2138,"impliedVolPercentile":0.6825},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBIO\",,,,,undefined,":{"symbol":"SBIO","floatShares":3600000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.807192,"shares":3600000,"dividePrice":0,"high":67.665,"amplitude":0.010474,"preClose":67.31,"low":66.96,"week52Low":35.43,"pbRate":"--","week52High":70.85,"institutionHeld":0,"latestPrice":67.66,"eps":0,"divideRate":0,"volume":26679,"delay":0,"ttmEps":0,"open":66.98,"prevYearClose":51.22,"prevWeekClose":67.09,"prevMonthClose":66.82,"prevQuarterClose":64.65,"fiveDayClose":67.09,"twentyDayClose":67.614,"sixtyDayClose":50.5209},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SBIO\",params:#limit:5,,,undefined,":[{"date":"2024-12-19","symbol":"SBIO","amount":1.17346,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-19","defaultRemindTime":1734618600000,"name":"ALPS Medical Breakthroughs ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-19","currency":"USD","dateTimestamp":1734584400000,"payDate":"2024-12-26"},{"date":"2023-12-21","symbol":"SBIO","amount":0.07106,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-22","defaultRemindTime":1703169000000,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2023-12-27","payableDate":"2023-12-22","currency":"USD","dateTimestamp":1703134800000,"payDate":"2023-12-27"},{"market":"US","date":"2019-12-19","symbol":"SBIO","amount":0.01585,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2019-12-27","payableDate":"2019-12-20","currency":"USD","type":"dividend","dateTimestamp":1576731600000},{"market":"US","date":"2018-12-20","symbol":"SBIO","amount":0.78406,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2018-12-27","payableDate":"2018-12-21","currency":"USD","type":"dividend","dateTimestamp":1545282000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SBIO\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.78406,"currency":"USD"},{"executeDate":"2019-12-19","recordDate":"2019-12-20","paymentDate":"2019-12-27","value":0.01585,"currency":"USD"},{"executeDate":"2023-12-21","recordDate":"2023-12-22","paymentDate":"2023-12-27","value":0.07106,"currency":"USD"},{"executeDate":"2024-12-19","recordDate":"2024-12-19","paymentDate":"2024-12-26","value":1.17346,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SBIO\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SBIO\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664388058","title":"109亿美元重磅收购Apogee(APGE.US)落地！艾伯维(ABBV.US)完成2019年以来最大并购，预计2032年起贡献收益","url":"https://stock-news.laohu8.com/highlight/detail?id=2664388058","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664388058?lang=zh_cn&edition=fundamental","pubTime":"2026-09-04 09:35","pubTimestamp":1788485746,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B19Z3B42.SGD","PJP","JDOC","TRUH","LU0124676726.USD","LU2129689605.HKD","SG9999003800.SGD","LU1267930490.SGD","ABBV","XLV","SBIO","IE0002141913.USD","APGE","LU1839511570.USD","PPH","CALF","LU1551013425.SGD","LU0320765646.SGD","LU0170899867.USD","LU1496350502.SGD","IXJ","LU0128525929.USD","BK4533","IE000WAW04H5.SGD","LU2087621335.USD","LU2089984988.USD","XMMO","MYLD","VHT","LU1236620834.HKD","LU0820561909.HKD","FTXH","RXL","LU2237443895.HKD","KCE","LU0203345920.USD","LU0859254822.USD","LU0114720955.EUR","LU2129689514.USD","AGNG","MEDX","IYH","LU0069063385.USD","LU2125909593.SGD","LU2433249047.HKD","GLAM","FHLC","LU0234570918.USD","LU0310800379.SGD","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664053388","title":"109亿美元重磅收购Apogee(APGE.US)落地！艾伯维(ABBV.US)完成2019年以来最大并购，预计2032年起贡献收益","url":"https://stock-news.laohu8.com/highlight/detail?id=2664053388","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664053388?lang=zh_cn&edition=fundamental","pubTime":"2026-09-04 09:35","pubTimestamp":1788485746,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，艾伯维于周四表示，公司已完成对抗炎药物研发商 Apogee Therapeutics价值 109 亿美元的收购。笔交易是这家制药巨头自 2019 年以来规模最大的补强型收购，智通财经AAPP于今年 6 月首次对此进行了报道。艾伯维预计，该项收购将对其调整后稀释每股收益产生负面影响，其中 2026 年将减少 0.14 美元，2027 年减少约 0.46 美元，并预计将于 2032 年开始实现增益。该指引已包含与完成 Apogee 收购相关的每股 0.14 美元稀释效应。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4559","LU1934455194.USD","KCE","LU1718418525.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IXJ","LU0124676726.USD","IYH","APGE","XMMO","BK4566","LU1989772840.SGD","PJP","AGNG","SG9999011175.SGD","ABBV","VHT","LU0965509283.SGD","LU0170899867.USD","IE00BLSP4239.USD","IE0002270589.USD","CALF","LU1003077747.HKD","FHLC","LU0289739343.SGD","LU2089283258.USD","IE00BN8TJ469.HKD","LU1037948541.HKD","BK4581","TRUH","LU0203345920.USD","IE0004445239.USD","LU0985320562.USD","MEDX","LU1983299246.USD","FTXH","JDOC","GLAM","XLV","SBIO","LU0256863902.USD","LU2237443549.SGD","PPH","RXL","IE00B19Z3581.USD","LU0057025933.USD","MYLD","LU1093756168.USD","LU1236620834.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664521258","title":"美股异动丨诺华制药涨超7%，多发性硬化症口服药后期临床试验结果积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2664521258","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664521258?lang=zh_cn&edition=fundamental","pubTime":"2026-09-01 22:18","pubTimestamp":1788272338,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00B4R5TH58.HKD","LU2272731600.USD","LU2473716301.USD","IE00BJJMRZ35.SGD","RXL","MRNY","PBPH","PPH","IBB","SBIO","BBH","IE0002141913.USD","TMED","HELX","LU0070302665.USD","BBP","FBT","BIB","IYH","MEDX","PJP","NVS","LU0211331839.USD","RSPH","SYNB","BIOY","XPH","AZNH","BK4588","FTXH","PSCH","IEHS","CANC","BME","LU2322448957.HKD","IE0009355771.USD","IEIH","XBIX","MRNX","IBRN","LFSC","WDNA","GNOM","IE00BJT1NW94.SGD","IDNA","MEDI","PBE","BK4585","IE00BFTCPJ56.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663282078","title":"药闻 | 英硅智能上市后首份半年报扭亏 创新药研发加速拥抱AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2663282078","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663282078?lang=zh_cn&edition=fundamental","pubTime":"2026-08-31 15:35","pubTimestamp":1788161758,"startTime":"0","endTime":"0","summary":"新华财经上海8月31日电（记者杜康）作为AI制药领域代表性企业之一，英硅智能（03696.HK）日前发布2026年度中期业绩报告。上半年，公司实现总营收1.063亿美元，同比增长287.2%；净利润3554万美元，经调整净利润5123万美元，经营活动现金流转正。这是英硅智能上市后发布的首份半年报，公司也由此前的亏损转为盈利。从收入结构看，药物研发与管线开发仍是主要来源。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860072952.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860072952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GDOC","AGIX","PBE","QTOC","XLVI","BBP","LFSC","BIOY","GSKH","BK4588","APXH","AIPO","IBB","BK4585","SBIO","WRND","IPOS","ARTY","VTHR","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044177","title":"联环药业上半年扭亏为盈 集采续采与创新药研发协同推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044177","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663044177?lang=zh_cn&edition=fundamental","pubTime":"2026-08-30 21:12","pubTimestamp":1788095520,"startTime":"0","endTime":"0","summary":"业绩实现扭亏为盈经营基本面持续改善今年上半年，联环药业经营业绩实现明显改善。对此，联环药业正持续推进相关工作。值得注意的是，联环药业已经开始围绕创新药商业化进行营销体系布局。除LH-1801外，联环药业产品注册申报也取得阶段性进展。从核心产品稳定销售，到集采品种持续放量，再到创新药研发向上市申报环节推进，联环药业正在逐步形成多层次的业务增长支撑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GDOC","BBP","BK0239","600513","WRND","XLVI","PBE","LFSC","GSKH","BK4588","APXH","BK4585","IBB","BIOY","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662752987","title":"博济医药2026年半年报：创新药研发需求复苏，在手订单充足，经营现金流明显下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662752987","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662752987?lang=zh_cn&edition=fundamental","pubTime":"2026-08-27 14:57","pubTimestamp":1787813849,"startTime":"0","endTime":"0","summary":"然而，需警惕新药研发政策变化、项目执行延期及市场竞争加剧带来的风险，同时关注经营现金流与净利润背离的情况。后续需重点关注公司在手订单转化进度、临床前及临床研究服务的毛利率变化趋势，以及经营现金流的改善情况。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787797151251328663","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["GDOC","SPHQ","IBB","SBIO","BK0216","GSKH","159399","LFSC","XLVI","BIOY","WRND","BBP","BK4585","300404","APXH","PBE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659504119","title":"中国银河证券：实验动物为创新药研发刚需 小鼠+猴双主线高景气","url":"https://stock-news.laohu8.com/highlight/detail?id=2659504119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659504119?lang=zh_cn&edition=fundamental","pubTime":"2026-08-14 15:07","pubTimestamp":1786691225,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，实验动物为创新药研发刚需，行业壁垒深厚，两大细分赛道具备中长期成长逻辑：人源化小鼠赛道成长确定性更强、周期波动平缓;实验猴赛道供给约束强，短期价格上行带来显著业绩弹性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LFSC","GSKH","BK1147","XLVI","06881","APXH","BK4588","SBIO","BK4585","IBB","PBE","161027","BK0276","BK1564","BK0188","GDOC","BBP","BIOY","WRND","601881"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903675","title":"百花医药股价严重异常波动：主营小分子化学仿制药CRO业务 不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903675","media":"央广财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658903675?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541220,"startTime":"0","endTime":"0","summary":"8月12日，百花医药（维权）（600721.SH）发布公告称，公司股票连续10个交易日内日收盘价格涨幅偏离值累计超过100%，根据上交所的有关规定，属于股票交易严重异常波动情形。公司是以小分子化学仿制药研发为主的CRO企业，不涉及创新药研发。公司2026年第一季度实现营业收入6718.29万元，同比下降30.68%，归属于上市公司股东的净利润664.27万元，同比下降67.94%。目前公司主营业务未发生重大变化，市场环境、行业政策没有发生重大调整，股价短期内连续上涨，涨幅与公司经营情况严重偏离。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-12/doc-ininamih5206238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SBIO","BK4585","LFSC","BK0216","GDOC","APXH","PBE","WRND","XLVI","BK4588","BIOY","GSKH","IBB","BK0102","600721","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658692990","title":"百花医药(600721.SH)：不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658692990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658692990?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["APXH","SBIO","LFSC","GDOC","GSKH","BK4585","IBB","BIOY","WRND","BBP","XLVI","BK4588","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658667990","title":"百花医药(600721.SH)：不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658667990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658667990?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百花医药(600721.SH)发布股票交易风险提示公告称，公司是以小分子化学仿制药研发为主的CRO企业，主营业务是为客户提供小分子化仿药为主的药物研发注册“一站式”全流程服务，主要研发项目多来自于客户委托加部分的公司自主立项，不涉及创新药研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["WRND","GDOC","BIOY","BK4588","BK4585","XLVI","SBIO","IBB","BBP","BK0102","GSKH","APXH","LFSC","PBE","BK0216","600721"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658962968","title":"东方证券：AI重构创新药研发底座 国内相关产业链公司亦有望受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2658962968","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658962968?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 14:06","pubTimestamp":1786428403,"startTime":"0","endTime":"0","summary":"东方证券主要观点如下：技术颠覆成本，AI重构制药“快与省”是中国创新药崛起的底层逻辑，根基是人才红利和成本优势。专家与AI协同，将真正提升新药研发的成功率并缩短周期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ARTY","BK1564","SBIO","AGIX","BK0012","VTHR","AIPO","BK1147","QTOC","IBB","BK0276","GDOC","03958","WRND","XLVI","BK0183","BK4588","BK0028","GSKH","LFSC","APXH","BK4585","CHAT","BIOY","BK0188","600958","PBE","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656375158","title":"券商观点：艾伯维免疫学研发管线实力雄厚，将支撑营收增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2656375158","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656375158?lang=zh_cn&edition=fundamental","pubTime":"2026-08-03 19:32","pubTimestamp":1785756750,"startTime":"0","endTime":"0","summary":"BUZZ-券商观点：艾伯维免疫学研发管线实力雄厚，将支撑营收增长8月3日-** 艾伯维（AbbVie）ABBV.N周五略微下调了其2026年盈利预期 (link)，以反映其计划收购Apogee Therapeutics的交易；同时，得益于免疫学药物销售强劲，该公司第二季度业绩超出市场预期免疫学业务表现稳健** Canaccord Genuity(维持“买入”评级，目标价：290美元) 指出，艾伯维","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL4S4400YQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBIO","TRUH","PPH","LU0417517546.SGD","LU2089283258.USD","RXL","FHLC","FTXH","LU0726765562.USD","LU1061106388.HKD","LU1093756325.SGD","LU1989772923.USD","LU0029864427.USD","LU1496350171.SGD","LU2237443978.SGD","LU0965508806.USD","ABBV","IE00BGHQF631.EUR","IE0004445239.USD","LU0211327993.USD","GLAM","IXJ","JDOC","LU1093756168.USD","VHT","AGNG","LU0689472784.USD","LU1670627923.USD","XLV","BK4534","LU1551013425.SGD","LU1267930490.SGD","LU0203345920.USD","IE00BLSP4452.SGD","PJP","IE00BJJMRZ35.SGD","APGE","IE00BVYPNV92.GBP","LU0053671581.USD","BK4533","LU0198837287.USD","MEDX","LU0912757837.SGD","SG9999003800.SGD","LU1003077747.HKD","LU0661504455.SGD","IYH","LU0472753341.HKD","LU1267930573.SGD","LU0057025933.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655365569","title":"艾伯维因收购Apogee下调2026年盈利预期，第二季度业绩超出预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2655365569","media":"路透中文","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655365569?lang=zh_cn&edition=fundamental","pubTime":"2026-07-31 19:49","pubTimestamp":1785498540,"startTime":"0","endTime":"0","summary":"艾伯维因收购Apogee下调2026年盈利预期，第二季度业绩超出预期预计2026年每股收益将因计划中的Apogee收购交易而减少14美分季度营收超出预期，达到169.9亿美元Humira销售额下滑36%至7.56亿美元，仍高于市场预期Skyrizi和Rinvoq的业绩也超出预期路透7月31日-艾伯维ABBV.N周五下调了2026年的盈利预期，以反映其计划收购Apogee Therapeutics的影响，同时得益于免疫学药物销售强劲，其第二季度业绩超出市场预期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL4S43X1CD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","LU0820561909.HKD","SG9999015952.SGD","PPH","APGE","IE00BSNM7G36.USD","RXL","FHLC","TRUH","IE0002141913.USD","LU0738911758.USD","IE00BVYPNW00.USD","FTXH","GLAM","LU0689626769.HKD","LU0689472784.USD","LU2129689431.USD","IE00BFTCPJ56.SGD","SG9999001440.SGD","LU1839511570.USD","PJP","MEDX","LU0203347892.USD","VHT","AGNG","IYH","LU0456855351.SGD","LU2087621335.USD","LU1732800096.USD","LU1718418525.SGD","LU0965509283.SGD","IXJ","LU1037948541.HKD","LU0170899867.USD","ABBV","IE000BZT7R73.USD","LU2347655156.SGD","SG9999015945.SGD","IE00B19Z3B42.SGD","LU1061106388.HKD","SBIO","IE000MB6IJN5.SGD","BK4588","JDOC","LU0122379950.USD","LU0211328371.USD","BK4559","XLV","LU1551013425.SGD","LU1670628061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653584157","title":"创新药研发加速遇“猴荒”","url":"https://stock-news.laohu8.com/highlight/detail?id=2653584157","media":"三里河","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653584157?lang=zh_cn&edition=fundamental","pubTime":"2026-07-22 16:21","pubTimestamp":1784708497,"startTime":"0","endTime":"0","summary":"“要站在‘猴’里，不要像猴子一样站在那里。”资本市场从来不缺故事。近期，昭衍新药业绩暴增，原因是实验猴市场价格上涨，带动公司手里的“猴子资产”大幅增值，多家相关概念公司股价也跟风大涨。甚至有人顺藤摸瓜，挖出了“香蕉概念”。网友戏称：这是产业链挖掘最深的一次。一只猴子，为什么能扰动资本市场？答案藏在药物的研发链条里。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607223817277458.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607223817277458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["WRND","GDOC","BIOY","BK4588","BK4585","XLVI","SBIO","IBB","BBP","GSKH","APXH","LFSC","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196709641","title":"ANI Pharmaceuticals 宣布拟就CG Oncology相关裁决提出上诉","url":"https://stock-news.laohu8.com/highlight/detail?id=1196709641","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196709641?lang=zh_cn&edition=fundamental","pubTime":"2026-07-17 06:34","pubTimestamp":1784241277,"startTime":"0","endTime":"0","summary":"ANI Pharmaceuticals Inc. 宣布，计划就与CG Oncology Inc.相关诉讼中的裁决提出上诉。此前，初审法院已驳回该公司提出的重新审理及判决的动议。\n该公司表示，将继续寻求追回其在2010年出售给CG Oncology的资产价值。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","SBIO","LU0566484027.USD","CGON","BK4139","ANIP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651162210","title":"英硅智能早盘涨超7% 与康哲药业达成AI+创新药研发新合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2651162210","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651162210?lang=zh_cn&edition=fundamental","pubTime":"2026-07-13 10:02","pubTimestamp":1783908120,"startTime":"0","endTime":"0","summary":"　　英硅智能早盘涨超7%，截至发稿，股价上涨6.21%，报45.48港元，成交额3.32亿港元。　　7月13日，据英硅智能官微消息，公司宣布与康哲药业在中枢神经系统领域开展另一项AI驱动的药物发现合作。　　根据合作协议，双方将结合英硅智能已验证的AI平台与AI赋能创新药研发能力，以及康哲药业经验丰富的研发团队和对疾病领域的深度认知，双方共同推进该研发项目的合作开发。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-13/doc-inihrnpk9058117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BMCWC346.EUR","BK1593","IE00BVYPNQ40.USD","BK1191","AIPO","BK4585","SG9999015945.SGD","BK4588","00867","GSKH","LFSC","IE00BVYPNP33.GBP","SBIO","AGIX","IBB","IE00BYV24P56.USD","ARTY","WRND","SG9999004220.SGD","QTOC","IE00BGHQDM52.EUR","SG9999015952.SGD","GDOC","SG9999015986.USD","CHAT","PBE","LU2488822045.USD","SG9999015978.USD","BBP","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649952006","title":"（活力中国调研行）上海生物医药产业规模破万亿 张江药谷青年人才成创新药研发主力","url":"https://stock-news.laohu8.com/highlight/detail?id=2649952006","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649952006?lang=zh_cn&edition=fundamental","pubTime":"2026-07-08 11:56","pubTimestamp":1783482969,"startTime":"0","endTime":"0","summary":"中新网上海7月8日电(杨海燕马佳佳)“我们对青年人才‘如饥似渴’，上海团队有180多名全职员工，90%以上都是40岁以下的青年人才。”英硅智能全球对外合作负责人、副总裁王珏7日在“活力中国调研行”主题采访活动中介绍道。在上海张江药谷，这片曾经的农田已崛起为世界级生物医药创新高地，而活跃其中的青年人才，正成为推动创新药研发的主力军。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607083798154946.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798154946.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","399441","WRND","BK4581","BK4588","LFSC","SBIO","BBP","GDOC","PBE","IBB","161726","XBI","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649984355","title":"翰思艾泰-B(03378)：拟与华科前沿交叉研究中心打造新一代AI驱动的创新药研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2649984355","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649984355?lang=zh_cn&edition=fundamental","pubTime":"2026-07-07 18:57","pubTimestamp":1783421872,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B 发布公告，为充分发挥产学研结合的优势，加速生物医药研发创新，公司于近日与华科—澳城大高等研究院前沿交叉研究中心正式签署了《“人工智能药物研发联合实验室”合作共建协议》。双方将依托华科前沿交叉研究中心的AI平台，以及翰思艾泰在创新药研发的丰富经验和对疾病领域的深度认知，围绕抗体发现与分子设计展开深度合作，共同打造新一代AI驱动的创新药研发范式。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SBIO","BK4588","VTHR","PBE","GSKH","BK1535","WRND","BBP","BK1173","IBB","CHAT","AIPO","GDOC","03378","QTOC","BK1161","LFSC","AGIX","ARTY","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}]}}